A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults >= 65 years of age

摘要

Objective: To assess the safety and immunogenicity of the MF59 (R)-adjuvanted trivalent influenza vaccine (aTIV; Fluad (R)) compared with modified aTIV formulations.